Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Cecilia
C
Roos
Leif
L
Stenke
Lotta
L
Ohm
Susanne
S
Widell
Maria
M
Kumlin
Jan Ake
JA
Lindgren
Susanne
S
Tornhamre
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005982:Glutathione Transferase / Q000096:biosynthesis*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D005982:Glutathione Transferase; C041116:leukotriene-C4 synthase